FGFR4 and hepatocellular carcinoma: In addition, Chen et al. discovered that in HCC, FGFR4 and its ligand FGF19 transactivate the SOX18 promoter directly by activating the p-FRS2/p-GSK3β/Wnt/β-catenin pathway.